ERBB2 and ovarian cancer: Approved (FDA) as single agent since 2017 in advanced platinum-sensitive ovarian cancerPhase III as single agent in BRCAmut/HER2-ve mutated TNBC, In combination with Dostarlimab or bevacizumab or atezolizumab in ovarian cancer, with pembrolizumab in NSCLC, with abriratrone and prednisone in HRR gene mutated CRPC, in combination with Dostarlimab